Polymeric Nanoparticles with Tunable Glass Transition for Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing nanoparticle systems that effectively deliver therapeutic agents to specific tissues or cells while minimizing side effects and maintaining stability for controlled release remains a challenge, particularly in cancer treatment where cytotoxic drugs need to target cancer cells without harming surrounding tissues.
Innovation Solution
The method involves preparing nanoparticle suspensions with block copolymers such as poly(D,L-lactic acid) and poly(ethylene glycol) to achieve specific glass transition temperatures, allowing for controlled drug release rates by varying the molecular weights of the polymers, resulting in fast, moderate, or slow release profiles depending on the application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high quantity of therapeutic agent is loaded into nanoparticle, then drug delivery effectiveness is improved, but nanoparticle size becomes too large for practical therapeutic use
Solution Approach 1:
The patent adjusts the glass transition temperature (Tg) of the polymeric matrix as a key parameter to control drug release and loading. By selecting polymers with specific Tg ranges (above or below physiological temperature), the system optimizes both drug loading capacity and nanoparticle size for effective delivery
Solution Approach 2:
The patent uses block copolymers comprising hydrophobic segments (for drug loading) and hydrophilic segments (for stability and biocompatibility). This composite structure enables high drug loading while maintaining appropriate nanoparticle size and stability in physiological environments
2Stability of the object's composition
If nanoparticle remains stable to limit rapid release, then controlled release is improved, but drug delivery rate may be too slow for effective treatment
Solution Approach 1:
The patent exploits changes in the glass transition temperature (Tg) of the polymeric matrix to control drug release kinetics. By selecting polymers with Tg above or below physiological temperature, the system achieves either sustained stable release or rapid release profiles, respectively, allowing optimization for different therapeutic requirements
Solution Approach 2:
The patent creates dynamic release profiles by utilizing the temperature-dependent glass transition of the polymer matrix. The nanoparticle system can transition between stable and release states based on temperature conditions, enabling controlled delivery that adapts to physiological conditions
3Reliability
If cytotoxic dose is delivered to cancer cells, then treatment efficacy is improved, but surrounding non-cancerous tissue is damaged
Solution Approach 1:
The patent employs targeted delivery where nanoparticles accumulate specifically at the tumor site through passive targeting (EPR effect) or active targeting mechanisms. The cytotoxic drug is released locally at the cancer site rather than systemically, maximizing therapeutic efficacy while minimizing exposure and damage to healthy surrounding tissues
Solution Approach 2:
The polymeric nanoparticle acts as an intermediary carrier that protects the cytotoxic drug during circulation and enables controlled release only at the target site. This intermediary system allows delivery of effective cytotoxic doses while reducing direct contact with and damage to healthy tissues
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.